[go: up one dir, main page]

DE69813868D1 - Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten - Google Patents

Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten

Info

Publication number
DE69813868D1
DE69813868D1 DE69813868T DE69813868T DE69813868D1 DE 69813868 D1 DE69813868 D1 DE 69813868D1 DE 69813868 T DE69813868 T DE 69813868T DE 69813868 T DE69813868 T DE 69813868T DE 69813868 D1 DE69813868 D1 DE 69813868D1
Authority
DE
Germany
Prior art keywords
mitogeneses
cytokines
inhibition
immune responses
pathological immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69813868T
Other languages
English (en)
Other versions
DE69813868T2 (de
Inventor
A Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE69813868D1 publication Critical patent/DE69813868D1/de
Publication of DE69813868T2 publication Critical patent/DE69813868T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22Immunosuppressive or immunotolerising
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/416Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/15Transforming growth factor beta (TGF-β)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/599Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69813868T 1997-11-05 1998-11-05 Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten Expired - Lifetime DE69813868T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05
US64507P 1997-11-05
PCT/US1998/023584 WO1999025366A1 (en) 1997-11-05 1998-11-05 Use of cytokines and mitogens to inhibit pathological immune responses

Publications (2)

Publication Number Publication Date
DE69813868D1 true DE69813868D1 (de) 2003-05-28
DE69813868T2 DE69813868T2 (de) 2004-03-04

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69813868T Expired - Lifetime DE69813868T2 (de) 1997-11-05 1998-11-05 Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten

Country Status (11)

Country Link
US (1) US6228359B1 (de)
EP (1) EP1028738B1 (de)
JP (1) JP4309047B2 (de)
AT (1) ATE238061T1 (de)
AU (1) AU747767B2 (de)
CA (1) CA2309115C (de)
DE (1) DE69813868T2 (de)
DK (1) DK1028738T3 (de)
ES (1) ES2198774T3 (de)
PT (1) PT1028738E (de)
WO (1) WO1999025366A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) * 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
DE69941113D1 (de) 1998-03-03 2009-08-27 Univ Southern California Zytokinen und mitogenen um "graft-versus-host disease" zu verhindern
WO2000066158A2 (en) * 1999-05-05 2000-11-09 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
DE60042210D1 (de) * 1999-09-01 2009-06-25 Univ Southern California Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
EP1274833B1 (de) * 2000-04-11 2010-03-10 University Of Southern California Methode zur verhinderung der transplantatabstossung unter verwendung von tgf-beta zur induktion von t-suppressorzellen
AU2002364230B2 (en) * 2001-12-21 2008-05-01 University Of Southern California Methods for the induction of professional and cytokine-producing regulatory cells
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
WO2011133808A1 (en) 2010-04-22 2011-10-27 University Of Southern California Methods and compositions for expanding and stabilizing natural regulatory t cells
WO2013050529A2 (en) 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
JP2014530360A (ja) 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA 診断マーカーとしてのoxMIF
US20150110738A1 (en) 2012-05-04 2015-04-23 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
AU747767B2 (en) 2002-05-23
ATE238061T1 (de) 2003-05-15
CA2309115A1 (en) 1999-05-27
DE69813868T2 (de) 2004-03-04
CA2309115C (en) 2010-10-19
PT1028738E (pt) 2003-08-29
WO1999025366A1 (en) 1999-05-27
EP1028738B1 (de) 2003-04-23
JP4309047B2 (ja) 2009-08-05
JP2001523443A (ja) 2001-11-27
US6228359B1 (en) 2001-05-08
EP1028738A1 (de) 2000-08-23
DK1028738T3 (da) 2003-08-11
AU1382799A (en) 1999-06-07
ES2198774T3 (es) 2004-02-01

Similar Documents

Publication Publication Date Title
DE69813868D1 (de) Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
ES2099158T3 (es) Tratamiento del rechazo de trasplantes o de enfermedades autoinmunitarias y complejo de la formula general x-pro-y-boropro asociada al mismo.
DE69929681D1 (de) Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE69435270D1 (de) Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
NZ294446A (en) Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
DE69014030D1 (de) Mittel für die Verhütung und Behandlung von Diarrhöe.
ES2149888T3 (es) 3-(3,4-dioxifenil)-pirrolidinas como inhibidores de la fosfodiesterasa de tipo iv para el tratamiento de enfermedades inflamatorias.
ATE190357T1 (de) Schnelles verfahren fur die dns sequenzierung und diagnostische anwendungen
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
IL143748A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
EP0702566A4 (de) Inhibition des migrations-inhibitions-faktors in der behandlung von krankheiten bei denen eine cytokin-vermittelte toxizität eine rolle spielt
IT8121396A0 (it) Procedimento per il trattamento, in particolare per la rigenerazione di olio usato.
DE69920205D1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
FR2491334B1 (de)
ATE53302T1 (de) Mittel zur behandlung von wunden.
DE60039863D1 (de) Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
ATE123942T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
IT8323342A0 (it) Impianto per il trattamento dei rifiuti e dei fanghi biologici.
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE69012883D1 (de) Methode für die Behandlung von Abgas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition